JOSEPH MCCRARY MCCUNE, MD
Osteopathic Medicine at Potrero Ave, San Francisco, CA
License number
California A41116
Category
Osteopathic Medicine
Type
Internal Medicine
Address
Address
1001 Potrero Ave RM 5H22, San Francisco, CA 94110
Phone
(415) 206-8317
(415) 206-8965 (Fax)
(415) 206-3103
(415) 206-3872 (Fax)
(415) 206-8965 (Fax)
(415) 206-3103
(415) 206-3872 (Fax)
Personal information
See more information about JOSEPH MCCRARY MCCUNE at radaris.comName
Address
Phone
2646 Union St, San Francisco, CA 94123
1400 Morningside Mtn, Glen Ellen, CA 95442
Sonoma, CA
410 Calle Fortuna, Hemet, CA 92545
Professional information
Extended Human Hematopoiesis In A Heterologous Host
US Patent:
5476997, Dec 19, 1995
Filed:
May 17, 1994
Appl. No.:
8/245250
Inventors:
Hideto Kaneshima - Palo Alto CA
Reiko Namikawa - Palo Alto CA
Joseph M. McCune - San Francisco CA
Reiko Namikawa - Palo Alto CA
Joseph M. McCune - San Francisco CA
Assignee:
Systemix, Inc. - Palo Alto CA
International Classification:
A61K 3500
US Classification:
800 2
Abstract:
A human hematopoietic system is provided in an immunocompromised mammalian host, where the hematopoietic system is functional for extended periods of time. Particularly, human fetal liver tissue and human fetal thymus is introduced into an appropriate site of a young immunocompromised mouse at a site supplied with a vascular system, whereby the fetal tissue results in novel formation of functional human bone marrow tissue.
Extended Human Hematopoiesis In A Heterologous Host
US Patent:
6093872, Jul 25, 2000
Filed:
Feb 13, 1992
Appl. No.:
7/836195
Inventors:
Hideto Kaneshima - Palo Alto CA
Reiko Namikawa - Palo Alto CA
Joseph McCrary McCune - San Francisco CA
Reiko Namikawa - Palo Alto CA
Joseph McCrary McCune - San Francisco CA
Assignee:
Systemix, Inc. - Palo Alto CA
International Classification:
A01K 6700, C12N 500
US Classification:
800 8
Abstract:
A human hematopoietic system is provided in an immunocompromised mammalian host, where the hematopoietic system is functional for extended periods of time. Particularly, human fetal liver tissue and human fetal thymus is introduced into an appropriate site of a young immunocompromised mouse at a site supplied with a vascular system, whereby the fetal tissue results in novel formation of functional human bone marrow tissue.
Human Lymphoid Tissue In An Immunocompromised Host
US Patent:
5411749, May 2, 1995
Filed:
Dec 23, 1992
Appl. No.:
7/996831
Inventors:
Susan K. Mayo - Portland OR
Reiko Namikawa - Palo Alto CA
Hideto Kaneshima - Palo Alto CA
Joseph M. McCune - San Francisco CA
Reiko Namikawa - Palo Alto CA
Hideto Kaneshima - Palo Alto CA
Joseph M. McCune - San Francisco CA
Assignee:
Systemix, Inc. - Palo Alto CA
International Classification:
A61K 3500, A61K 3900, A61K 4900
US Classification:
424578
Abstract:
Human lymphoid tissue is introduced into an immunocompromised host to provide opportunities to investigate the effect of stimuli on the human immune system and obtain information and products from the stimulus. Particularly, methodology is provided for the production of human monoclonal antibodies by introducing lymphoid tissue into an immunocompromised host, stimulating the B-lymphocytes with an appropriate immunogen, harvesting the tissue and immortalizing and/or cloning the B-lymphocytes under conditions to obtain a stable supply of monoclonal antibodies.
Small Animal Metastasis Model
US Patent:
5643551, Jul 1, 1997
Filed:
Oct 26, 1994
Appl. No.:
8/329679
Inventors:
Reiko Namikawa - Palo Alto CA
Seishi Kyoizumi - Aki-gun, JP
Emilya Shtivelman - Belmont CA
Joseph M. McCune - San Francisco CA
Seishi Kyoizumi - Aki-gun, JP
Emilya Shtivelman - Belmont CA
Joseph M. McCune - San Francisco CA
Assignee:
Systemix, Inc. - Palo Alto CA
International Classification:
A01N 5700, A61K 3800, C12N 500, C12N 1506
US Classification:
424 91
Abstract:
A method for initiating metastasis of human tumor cells under experimental conditions is provided. Immunocompromised non-human mammals having a viable, xenogeneic organ or tissue are used as a host for human tumor cells. The cells are introduced into the chimeric animal after the solid tissue is implanted and are then able to grow and metastasize as they would in situ. Therapeutic regimens may be evaluated in this system to determine efficacy against metastatic processes.
Extended Human Hematopoiesis In A Heterologous Host
US Patent:
5625127, Apr 29, 1997
Filed:
May 4, 1995
Appl. No.:
8/434706
Inventors:
Hideto Kaneshima - Palo Alto CA
Reiko Namikawa - Palo Alto CA
Joseph M. McCune - San Francisco CA
Reiko Namikawa - Palo Alto CA
Joseph M. McCune - San Francisco CA
Assignee:
SyStemix, Inc. - Palo Alto CA
International Classification:
A61K 3500
US Classification:
800 2
Abstract:
A human hematopoietic system is provided in an immunocompromised mammalian host, where the hematopoietic system is functional for extended periods of time. Particularly, human fetal liver tissue and human fetal thymus is introduced into an appropriate site of a young immunocompromised mouse at a site supplied with a vascular system, whereby the fetal tissue results in novel formation of functional human bone marrow tissue.
Method For Measuring De Novo T-Cell Production In Humans
US Patent:
2003022, Dec 11, 2003
Filed:
Jan 13, 2003
Appl. No.:
10/341015
Inventors:
Rafick-Pierre Sekaly - St. Laurent, CA
Jean-Francois Poulin - Montreal, CA
Morgan Jenkins - San Francisco CA, US
Jeffrey Harris - San Francisco CA, US
Krishna Komanduri - San Francisco CA, US
Joseph McCune - San Francisco CA, US
Jean-Francois Poulin - Montreal, CA
Morgan Jenkins - San Francisco CA, US
Jeffrey Harris - San Francisco CA, US
Krishna Komanduri - San Francisco CA, US
Joseph McCune - San Francisco CA, US
International Classification:
C12Q001/68, C12P019/34
US Classification:
435/006000, 435/091200
Abstract:
The present invention relates to a method for measuring de novo T-cell production in humans, and more particularly to the assessement recent thymic emigrant (RTE) diversity in a T-cell sub-population of a patient by the detection of T-cell receptor chain DNA deletion circles (TCRDC) generated during TCR gene rearrangement of thymocytes in the thymus. The method comprises isolating a T-cell sub-population from a patient, extracting genomic DNA from the T-cell sub-population, amplifying the genomic DNA with a primer specific for a T-cell receptor chain DNA rearrangement deletion circle (TCRDC) family and detecting the TCRDC, the TRCDC being indicative of the presence of a RTE. The method assesses the quantitative and qualitative (diversity) intrathymic T-cell production by quantitating the relative frequency and diversity of RTEs within various sub-populations of circulating human T-cells. Such a method may be useful to study the diversity of the human thymic function and to monitor immune reconstitution of HIV patients.
Chimeric Immunocompromised Mammal Comprosing Vascularized Fetal Organ Tissue
US Patent:
5639939, Jun 17, 1997
Filed:
Mar 1, 1994
Appl. No.:
8/205053
Inventors:
Joseph M. McCune - San Francisco CA
Assignee:
The Board of Trustees for the Leland Stanford Junior University - Palo Alto CA
International Classification:
A61K 4900
US Classification:
800 2
Abstract:
Xenogeneic tissue is introduced into an immunocompromised host for interacting with agents and using such interaction for evaluating efficacy of drugs and vaccines, producing xenogeneic monoclonal antibodies, evaluating the effect of the various agents on specific tissues and the like. Particularly, drugs can be evaluated for their efficacy against a wide variety of pathogens which infect xenogeneic tissue, agents can be evaluated for their effect on the xenogeneic immune system and monoclonal antibodies to a predetermined epitope may be produced.
Method For Screening Potential Therapeutically Effective Antiviral Agents
US Patent:
5601975, Feb 11, 1997
Filed:
Jun 6, 1995
Appl. No.:
8/466420
Inventors:
Mark L. Bonyhadi - Belmont CA
Joseph M. McCune - San Francisco CA
Hideto Kaneshima - Palo Alto CA
Joseph M. McCune - San Francisco CA
Hideto Kaneshima - Palo Alto CA
Assignee:
SyStemix, Inc. - Palo Alto CA
International Classification:
C12Q 170
US Classification:
435 5
Abstract:
The invention provides methods for screening agents for potential anti-viral effects by assessing the ability of the agents to suppress viral replication and/or pathology in thymic cells grown in thymic organ culture in vitro. Also provided are methods to study viral pathology and infectivity.
Drug Screening And Treatment For Hiv Thymocyte Depletion
US Patent:
5612018, Mar 18, 1997
Filed:
Jan 18, 1994
Appl. No.:
8/183178
Inventors:
Mark L. Bonyhadi - Belmont CA
Hideto Kaneshima - Palo Alto CA
Joseph M. McCune - San Francisco CA
Reiko Namikawa - Palo Alto CA
Lishan Su - Palo Alto CA
Hideto Kaneshima - Palo Alto CA
Joseph M. McCune - San Francisco CA
Reiko Namikawa - Palo Alto CA
Lishan Su - Palo Alto CA
Assignee:
Systemix, Inc. - Palo Alto CA
International Classification:
A61K 4900
US Classification:
424 92
Abstract:
A method is provided for screening compounds for the ability to supress thymocyte depletion in thymuses of HIV-infected individuals, particularly enhancing the CD4. sup. + -expressing population as compared to an untreated individual. Particularly, drugs are provided which allow for this result, cyclosporine A being exemplary.
Method For Screening Potential Therapeutically Effective Antiviral Agents
US Patent:
5645982, Jul 8, 1997
Filed:
Aug 19, 1993
Appl. No.:
8/109305
Inventors:
Mark L. Bonyhadi - Belmont CA
Joseph M. McCune - San Francisco CA
Hideto Kaneshima - Palo Alto CA
Joseph M. McCune - San Francisco CA
Hideto Kaneshima - Palo Alto CA
Assignee:
SyStemix, Inc. - Palo Alto CA
International Classification:
C12N 508
US Classification:
435 5
Abstract:
The invention provides methods for screening agents for potential anti-viral effects by assessing the ability of the agents to suppress viral replication and/or pathology in thymic cells grown in thymic organ culture in vitro. Also provided are methods to study viral pathology and infectivity.